Asymptotically Safe Standard Model via Vectorlike Fermions.

We construct asymptotically safe extensions of the standard model by adding gauged vectorlike fermions. Using large number-of-flavor techniques we argue that all gauge couplings, including the hypercharge and, under certain conditions, the Higgs coupling, can achieve an interacting ultraviolet fixed point.

Decoding the X(5568) as a Fully Open-Flavor sub[over ¯]d[over ¯] Tetraquark State.

We investigate the recent evidence for a charged X(5568) meson as an exotic open-flavor tetraquark state sub[over ¯]d[over ¯] with J^{P}=0^{+}/1^{+} in the framework of QCD sum rules. We use the color antisymmetric [3[over ¯]_{c}]_{su}⊗[3_{c}]_{b[over ¯]d[over ¯]} tetraquark currents in both scalar and axial-vector channels to perform evaluations and numerical analyses. Our results imply that the X(5568) can be interpreted as both the scalar sub[over ¯]d[over ¯] tetraquark state and the axial-vector one, which are in good agreement with the experimental measurement. We also discuss the possible decay patterns of the X(5568) and suggest to search for its neutral partner in the radiative decay into B_{s}^{0}γ and B_{s}^{*}γ, which can be used to determine its spin-parity quantum numbers. Moreover, we predict its charmed partner state around 2.55 GeV with the quark content suc[over ¯]d[over ¯] and J^{P}=0^{+}/1^{+}.

Towards Exotic Hidden-Charm Pentaquarks in QCD.

Inspired by P(c)(4380) and P(c)(4450) recently observed by LHCb, a QCD sum rule investigation is performed, by which they can be identified as exotic hidden-charm pentaquarks composed of an anticharmed meson and a charmed baryon. Our results suggest that P(c)(4380) and P(c)(4450) have quantum numbers J(P)=3/2(-) and 5/2(+), respectively. Furthermore, two extra hidden-charm pentaqurks with configurations D̅Σ(c)(*) and D̅(*)Σ(c)(*) are predicted, which have spin-parity quantum numbers J(P)=3/2(-) and J(P)=5/2(+), respectively. As an important extension, the mass predictions of hidden-bottom pentaquarks are also given. Searches for these partners of P(c)(4380) and P(c)(4450) are especially accessible at future experiments like LHCb and BelleII.

Viable dark matter via radiative symmetry breaking in a scalar singlet Higgs portal extension of the standard model.

We consider the generation of dark matter mass via radiative electroweak symmetry breaking in an extension of the conformal standard model containing a singlet scalar field with a Higgs portal interaction. Generating the mass from a sequential process of radiative electroweak symmetry breaking followed by a conventional Higgs mechanism can account for less than 35% of the cosmological dark matter abundance for dark matter mass M(s)>80 GeV. However, in a dynamical approach where both Higgs and scalar singlet masses are generated via radiative electroweak symmetry breaking, we obtain much higher levels of dark matter abundance. At one-loop level we find abundances of 10%-100% with 106 GeV80 GeV detection region of the next generation XENON experiment.

Is radiative electroweak symmetry breaking consistent with a 125 GeV Higgs mass?

The mechanism of radiative electroweak symmetry breaking occurs through loop corrections, and unlike conventional symmetry breaking where the Higgs mass is a parameter, the radiatively generated Higgs mass is dynamically predicted. Padé approximations and an averaging method are developed to extend the Higgs mass predictions in radiative electroweak symmetry breaking from five- to nine-loop order in the scalar sector of the standard model, resulting in an upper bound on the Higgs mass of 141 GeV. The mass predictions are well described by a geometric series behavior, converging to an asymptotic Higgs mass of 124 GeV consistent with the recent ATLAS and CMS Collaborations observations. Similarly, we find that the Higgs self-coupling converges to λ=0.23, which is significantly larger than its conventional symmetry breaking counterpart for a 124 GeV Higgs mass. In addition to this significant enhancement of the Higgs self-coupling and HH→HH scattering, we find that Higgs decays to gauge bosons are unaltered and the scattering processes WL(+)WL(+)→HH, ZLZL→HH are also enhanced, providing signals to distinguish conventional and radiative electroweak symmetry breaking mechanisms.

Radiative electroweak symmetry breaking revisited.

In the absence of a tree-level scalar-field mass, renormalization-group methods permit the explicit summation of leading-logarithm contributions to all orders of the perturbative series within the effective potential for SU(2)xU(1) electroweak symmetry. This improvement of the effective potential function is seen to reduce residual dependence on the renormalization mass scale. The all-orders summation of leading-logarithm terms involving the dominant three couplings contributing to radiative corrections is suggestive of a potential characterized by a plausible Higgs boson mass of 216 GeV. However, the tree potential's local minimum at phi=0 is restored if QCD is sufficiently strong.

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.

alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K(i) values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1b) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.